Francina Fonseca

Dr. Francina Fonseca

Institut de Neuropsiquiatria i Addiccions (INAD), Hospital del Mar
+2
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2005 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
MTMarta Torrens
Marta Torrens
Francina FonsecaFrancina Fonseca
Francina Fonseca
GMGerard Mateu
Gerard Mateu
MFMagí Farré
Magí Farré

16 February 2021 in Current Addiction Reports
Verified
Journal Article
Closed access
PDF file
Francina FonsecaFrancina Fonseca
Francina Fonseca
MRMaría Robles-Martínez
María Robles-Martínez
JTJudit Tirado-Muñoz
Judit Tirado-Muñoz
MAMaría Alías-Ferri
María Alías-Ferri
JMJoan Ignasi Mestre-Pinto
Joan Ignasi Mestre-Pinto
MTMarta Torrens
Marta Torrens

21 January 2020 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
JFJuan José Fuentes
Juan José Fuentes
Francina FonsecaFrancina Fonseca
Francina Fonseca
MEMatilde Elices
Matilde Elices
MFMagí Farré
Magí Farré
MTMarta Torrens
Marta Torrens
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and its therapeutic potential for psychiatry. The aim of this review is to identify controlled and randomized clinical trials that assess the potential use of LSD in psychiatry. PRISMA guidelines for systematic review were followed. A literature search of PubMed and Psychedelic bibliography from Multidisciplinary Association for Psychedelic Studies (MAPS) databases was performed as well as a manual search of references from evaluated studies. Only randomized-controlled clinical trials were included. Study quality was systematically calculated by using the Cochrane Collaboration Tool for assessing risk of bias. A final selection of 11 articles was made after considering inclusion and exclusion criteria. LSD was administered to 567 patients in a dose ranging from 20 to 800 mcg. Despite the design heterogeneity of clinical trials, positive results were observed, thus revealing the therapeutic potential of LSD to reduce psychiatric symptomatology, mainly in alcoholism. The vast majority of authors describe significant and positive short-term changes in patients, despite the fact that in some studies an important homogenization was observed between the LSD treatment group and control group at long-term follow-up. Multiple variables regarding LSD treatment therapeutic approach and quality of experience were revealed and related to therapeutic outcomes. LSD is revealed as a potential therapeutic agent in psychiatry; the evidence to date is strongest for the use of LSD in the treatment of alcoholism. Despite the difficulty of designing proper double blind clinical trials with this substance, new studies that conform to modern standards are necessary in order to strengthen our knowledge on its use and open new doors in the future.

20 May 2016 in Neuropsychopharmacology
Verified
Journal Article
Closed access
EPEsther Papaseit
Esther Papaseit
CPClara Pérez-Mañá
Clara Pérez-Mañá
JMJulián-Andrés Mateus
Julián-Andrés Mateus
MPMitona Pujadas
Mitona Pujadas
Francina FonsecaFrancina Fonseca
Francina Fonseca
MFMagi Farré
Magi Farré

1 August 2006 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SASergio Abanades
Sergio Abanades
MFMagi Farré
Magi Farré
MSMireia Segura
Mireia Segura
SPSimona Pichini
Simona Pichini
DBDiego Barral
Diego Barral
Renato TorreRenato Torre
Renato Torre

12 May 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Francina FonsecaFrancina Fonseca
Francina Fonseca
Renato TorreRenato Torre
Renato Torre
LDLaura Díaz
Laura Díaz
APAntoni Pastor
Antoni Pastor
ECElisabet Cuyas
Elisabet Cuyas
MTMarta Torrens
Marta Torrens
Although the efficacy of methadone maintenance treatment (MMT) in opioid dependence disorder has been well established, the influence of methadone pharmacokinetics in dose requirement and clinical outcome remains controversial. The aim of this study is to analyze methadone dosage in responder and nonresponder patients considering pharmacogenetic and pharmacokinetic factors that may contribute to dosage adequacy. Opioid dependence patients (meeting Diagnostic and Statistical Manual of Mental Disorders, [4th Edition] criteria) from a MMT community program were recruited. Patients were clinically assessed and blood samples were obtained to determine plasma concentrations of (R,S)-, (R) and (S)- methadone and to study allelic variants of genes encoding CYP3A5, CYP2D6, CYP2B6, CYP2C9, CYP2C19, and P-glycoprotein. Responders and nonresponders were defined by illicit opioid consumption detected in random urinalysis. The final sample consisted in 105 opioid dependent patients of Caucasian origin. Responder patients received higher doses of methadone and have been included into treatment for a longer period. No differences were found in terms of genotype frequencies between groups. Only CYP2D6 metabolizing phenotype differences were found in outcome status, methadone dose requirements, and plasma concentrations, being higher in the ultrarapid metabolizers. No other differences were found between phenotype and responder status, methadone dose requirements, neither in methadone plasma concentrations. Pharmacokinetic factors could explain some but not all differences in MMT outcome and methadone dose requirements.